drugset / Trial / NCT00527397

Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes

NCT00527397

Phase 3 Terminated 24 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)

Timeline

Start
2007-08
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled